The company uses its proprietary technology, LanthioPepTM, to generate novel peptide therapeutics that are resistant to degradation, highly specific to receptors, and have increased intrinsic activity. Lanthio Pharma has successfully developed stable, peptidase-resistant lanthionine peptides with specific agonistic activity for various GPCR targets. The company is a biopharmaceutical firm that specializes in discovering and developing Lantipeptides, a new class of peptides with drug-like properties. Lanthio Pharma spun out of the University of Groningen and is privately held.